Freezing tumors before chemo: new hope for esophageal cancer?
NCT ID NCT07222657
First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 4 times
Summary
This study tests whether freezing cancer cells with liquid nitrogen before chemotherapy can improve outcomes for people with advanced esophageal cancer. About 40 adults will be randomly assigned to receive either the freezing treatment plus chemotherapy or chemotherapy alone. The freezing is done during an endoscopy and aims to destroy tumor tissue, potentially leading to better response rates.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2026
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults with locally advanced EAC who are expected to receive FLOT +/-Durvalumab will be eligible to participate. * Locally advanced esophageal cancer is defined as TNM stages T1N+M0 or T2-T4aNanyM0, as defined by endoscopic ultrasound (EUS) and PET-CT. Exclusion Criteria: * Inability to pass the orogastric decompression tube into the stomach * Coagulopathy (INR \> 2 or platelet count \< 50,000 per cubic millimeter) * Inability to provide informed consent * Eastern Cooperative Oncology Group (ECOG) performance status \> 2 * Risk of thrombosis is determined to be too high to hold anti-platelets (other than aspirin) or anticoagulants prior to the procedure.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Cleveland Clinic Florida
RECRUITINGWeston, Florida, 33331, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood proteins may predict who beats esophageal cancer with chemoradiation
- New Antibody-Drug conjugate put to the test against Hard-to-Treat cancers
- Can a direct hit to tumors make immunotherapy work better?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Can a new drug boost immunotherapy against Hard-to-Treat stomach cancer?
- Can a guided missile for chemo hit tumors harder and spare healthy tissue?